THE RELATIONSHIP BETWEEN OF CANCERS AND RHEUMATIC DISEASES
https://doi.org/10.14412/1995-4484-2020-198-206
Abstract
The literature review considers the fundamental elements of a relationship between cancers and rheumatic diseases, including a variety of paraneoplastic syndromes, a profile of rheumatic diseases associated with the development of oncopathology, and autoimmune rheumatic syndromes detected in patients who receive anticancer therapy. Emphasis is placed on the need for interdisciplinary interaction to deepen understanding of the pathophysiological mechanisms of both groups of diseases and to improve medical care for patients.
About the Author
A. D. Koltakova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0
3. Kankeleit H. Uber primare nichteirige Polymyositis. Dtsch Arch Klin Med. 1916;120:335-49.
4. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0
6. Kankeleit H. Uber primare nichteirige Polymyositis. Dtsch Arch Klin Med. 1916;120:335-49.
7. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
8. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
9. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
10. doi: 10.1097/BOR.0000000000000329
11. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
12. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
13. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0
14. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
15. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0
17. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
18. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
19. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
20. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
21. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
22. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
23. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
24. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
25. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
26. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
27. Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859
28. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
29. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
30. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
31. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
32. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
33. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
34. Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002
35. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
36. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
37. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
38. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
39. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
40. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
41. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
42. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
43. Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292
44. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
45. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
46. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
47. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
48. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
49. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
50. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
51. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061
52. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
53. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
54. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
55. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
56. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
57. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
58. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
59. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
60. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
61. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
62. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
63. Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663
64. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
65. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
66. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
67. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
68. Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002
69. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
70. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
71. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
72. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
73. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
74. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
75. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
76. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
77. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0
78. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
79. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
80. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
81. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
82. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
83. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
84. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
85. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
86. Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.
87. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
88. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
89. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
90. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
91. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
92. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
93. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
94. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
95. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
96. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.
97. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
98. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
99. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
100. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
101. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
102. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
103. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
104. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
105. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384
106. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
107. doi: 10.1097/BOR.0000000000000329
108. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
109. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
110. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
111. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
112. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
113. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
114. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
115. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886
116. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
117. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
118. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
119. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
120. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
121. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
122. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3
123. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
124. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
125. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
126. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
127. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
128. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
129. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
130. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
131. Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131
132. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
133. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
134. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
135. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
136. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566
137. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
138. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
139. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
140. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
141. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
142. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
143. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
144. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
145. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.
146. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
147. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
148. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
149. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
150. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
151. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
152. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
153. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.x
154. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
155. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
156. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
157. doi: 10.1136/ard.2004.032995
158. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
159. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
160. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
161. Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)
162. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
163. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
164. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
165. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
166. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
167. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
168. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
169. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
170. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
171. Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8
172. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
173. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
174. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
175. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
176. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
177. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9
178. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
179. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
180. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
181. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
182. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
183. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
184. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
185. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305
186. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
187. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
188. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
189. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
190. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
191. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
192. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
193. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
194. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
195. Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)
196. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
197. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
198. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
199. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
200. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
201. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009
202. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
203. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
204. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
205. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
206. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
207. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
208. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
209. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
210. Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
211. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
212. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
213. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
214. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
215. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
216. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
217. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
218. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
219. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969
220. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
221. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
222. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
223. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
224. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
225. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
226. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
227. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7
228. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
229. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
230. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
231. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
232. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
233. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
234. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
235. Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069
236. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
237. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
238. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
239. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
240. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
241. doi: 10.1136/ard.2004.032995
242. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
243. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.
244. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
245. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
246. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
247. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
248. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
249. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
250. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.
251. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
252. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
253. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
254. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
255. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
256. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
257. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
258. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
259. Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402
260. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
261. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
262. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
263. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
264. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
265. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
266. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
267. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
268. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
269. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
270. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
271. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502
272. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
273. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
274. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
275. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
276. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
277. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
278. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164
279. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
280. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
281. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
282. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
283. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
284. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
285. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863
286. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
287. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
288. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
289. doi: 10.1097/BOR.0000000000000329
290. Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379
291. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
292. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
293. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
294. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
295. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
296. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
297. doi: 10.1097/BOR.0000000000000329
298. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
299. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009
300. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
301. doi: 10.1097/BOR.0000000000000329
302. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
303. doi: 10.1097/BOR.0000000000000329
304. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
305. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
306. doi: 10.1097/BOR.0000000000000329
307. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
308. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
309. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.
310. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
311. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
312. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
313. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
314. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
315. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
316. doi: 10.1097/BOR.0000000000000329
317. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
318. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
319. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
320. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
321. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
322. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
323. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697
324. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
325. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
326. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
327. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
328. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
329. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
330. Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210
331. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
332. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
333. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
334. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
335. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
336. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
337. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
338. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
339. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
340. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
341. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054
342. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
343. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
344. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
345. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
346. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6
347. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
348. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
349. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
350. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
351. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
352. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
353. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
354. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
355. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290
356. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
357. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
358. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
359. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
360. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
361. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085
362. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
363. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
364. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
365. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
366. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
367. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
368. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
369. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
370. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
371. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002
372. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
373. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
374. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
375. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
376. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
377. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
378. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
379. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
380. Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3
381. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
382. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
383. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
384. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
385. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
386. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
387. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
388. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
389. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
390. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277
391. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
392. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
393. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
394. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
395. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
396. Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086
397. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
398. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
399. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
400. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
401. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
402. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
403. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
404. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
405. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
406. Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672
407. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
408. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
409. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
410. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
411. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
412. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
413. Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6
414. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
415. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
416. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
417. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
418. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
419. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
420. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565
421. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
422. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
423. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
424. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
425. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
426. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
427. Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1
428. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
429. doi: 10.1136/ard.2004.032995
430. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
431. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
432. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
433. doi: 10.1136/ard.2004.032995
434. doi: 10.1136/ard.2004.032995
435. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
436. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006
437. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
438. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
439. doi: 10.1136/ard.2004.032995
440. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
441. doi: 10.1136/ard.2004.032995
442. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
443. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
444. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
445. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
446. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.
447. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
448. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
449. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
450. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
451. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
452. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
453. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
454. doi: 10.1136/ard.2004.032995
455. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
456. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
457. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
458. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
459. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
460. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
461. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
462. Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0
463. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
464. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
465. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
466. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
467. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
468. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
469. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
470. Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836
471. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
472. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
473. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
474. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
475. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-y
476. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
477. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
478. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
479. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
480. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
481. Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108
482. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
483. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
484. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
485. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
486. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
487. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
488. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
489. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
490. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
491. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
492. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
493. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012
494. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
495. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
496. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
497. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
498. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
499. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
500. Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060
501. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
502. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
503. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
504. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
505. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
506. Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.x
507. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
508. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
509. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
510. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
511. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
512. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
513. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
514. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
515. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
516. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
517. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006
518. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
519. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
520. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
521. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
522. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
523. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
524. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
525. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001
526. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
527. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
528. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
529. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
530. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
531. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
532. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
533. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
534. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
535. Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.x
536. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
537. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
538. Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781
539. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
540. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
541. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
542. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
543. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
544. Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515
545. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
546. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
547. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
548. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
549. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
550. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
551. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
552. Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424
553. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
554. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
555. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
556. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
557. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
558. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
559. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
560. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
561. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
562. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
563. Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516
564. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
565. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
566. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
567. Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6
568. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
569. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
570. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
571. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
572. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
573. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
574. Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.
575. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
576. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
577. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690
578. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
579. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
580. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
581. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
582. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
583. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
584. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
585. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
586. Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011
587. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
588. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
589. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
590. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
591. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
592. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
593. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
594. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
595. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
596. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
597. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
598. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
599. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768
600. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
601. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
602. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
603. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
604. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
605. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
606. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
607. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
608. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
609. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
610. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573
611. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
612. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
613. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
614. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
615. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
616. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691
617. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
618. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
619. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
620. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
621. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
622. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
623. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
624. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
625. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
626. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2
627. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
628. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
629. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
630. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
631. Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565
632. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
633. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
634. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
635. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
636. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
637. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
638. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
639. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999
640. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
641. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
642. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
643. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
644. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
645. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
646. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
647. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
648. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
649. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
650. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
651. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.
652. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
653. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
654. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
655. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
656. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
657. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668
658. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
659. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
660. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
661. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
662. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
663. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
664. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
665. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
666. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
667. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
668. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
669. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
670. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
671. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001
672. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
673. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
674. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
675. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
676. Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.
677. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
678. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
679. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
680. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
681. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
682. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
683. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025
684. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
685. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
686. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8
687. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
688. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
689. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
690. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
691. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
692. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
693. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
694. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221
695. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
696. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
697. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
698. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
699. Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)
700. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
701. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
702. Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005
703. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
704. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
Review
For citations:
Koltakova A.D. THE RELATIONSHIP BETWEEN OF CANCERS AND RHEUMATIC DISEASES. Rheumatology Science and Practice. 2020;58(2):198-206. (In Russ.) https://doi.org/10.14412/1995-4484-2020-198-206
Views:
1372
Email this article 